LGND

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company. Its business model is based upon the concept of acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals Incorporated (LGND) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
D-
Factor Score 1.1 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
B
Factor Score 3.5 / 5.0
Momentum
B+
Factor Score 3.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 127.0
EV / EBITDA 98.4
Rev Growth YoY -31.8%
Gross Margin 86.1%
Price Return 3M 7.4%
Price Return 12M 51.5%
Catalyst Signal 0.00
Market Cap $6.3B
TTM Revenue $253.8M
Price / Sales 24.9
ROE 5.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 D- (1.1) C (2.2) B (3.5) B+ (3.7) C+ (2.6) C+ (2.6)
2026-11-06 D- (1.1) C (2.2) B (3.5) B+ (3.7) C+ (2.7) C+ (2.6)
2026-10-30 C (2.2) B- (2.9) B+ (3.5) B+ (3.7) C+ (2.7) B- (3.0)
2026-10-23 C (2.3) B- (2.9) B+ (3.5) B (3.3) C+ (2.6) B- (2.9)
2026-10-16 C (2.3) B- (2.9) B+ (3.5) B- (3.0) C+ (2.6) B- (2.9)
Page 1 of 6